VTYX•benzinga•
Ventyx Biosciences Announces Presentation Of Data From The Phase 2 Trial Of Allosteric TYK2 Inhibitor VTX958 In Crohn's Disease At ECCO 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 18, 2025 by benzinga